Company news
Theravance Biopharma, Inc. news in 2022
Theravance Biopharma, Inc.'s news releases, calls and decks from 2022, newest first.
Theravance Biopharma, Inc. Announces Final Results of Tender Offer
November 21, 2022
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer
November 17, 2022
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer
November 6, 2022
Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System
November 1, 2022
Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022
October 30, 2022
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
October 24, 2022
Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
September 27, 2022
Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program
September 18, 2022
Theravance Biopharma to Present at Upcoming Investor Conferences
September 5, 2022
Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 3, 2022
Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022
July 27, 2022
Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023
July 25, 2022
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
July 12, 2022
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 4, 2022
Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022
May 1, 2022
Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)
April 3, 2022
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 22, 2022
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
February 8, 2022
Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study
January 9, 2022
Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Calls in 2022
- Theravance Biopharma (NASDAQ:TBPH) Q3 2022 Earnings Call
Nov 7, 2022
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q1 2022 Earnings Call
May 5, 2022
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q4 2021 Earnings Call
Feb 23, 2022
Transcript
Decks in 2022
- Q3 2022 Earnings Presentation
Earnings · 26 slides · Nov 7, 2022
- 33rd International Symposium on the Autonomic Nervous System (November 2022)
Conference · 44 slides · Nov 3, 2022
- Investor Presentation (September 2022)
Investor deck · 25 slides · Sep 13, 2022
- Q2 2022 Earnings Presentation
Earnings · 26 slides · Aug 4, 2022
- Merger or Acquisition (July 2022)
Merger or acquisition · 13 slides · Jul 13, 2022
- Q1 2022 Earnings Presentation
Earnings · 24 slides · May 5, 2022
- Technical Presentation (April 2022)
Technical · 9 slides · Apr 4, 2022
- FY2021 Earnings Presentation
Earnings · 21 slides · Feb 23, 2022
- Investor Presentation (January 2022)
Investor deck · 15 slides · Jan 10, 2022
- JP Morgan Healthcare Conference 2022
Conference · 24 slides · Jan 10, 2022